Emerging treatments
Redifferentiation therapy
Targeted therapies can be used to restore radioactive iodine (RAI) avidity in RAI-refractory patients, a therapeutic strategy termed "redifferentiation".[82] In one phase 2 trial, dabrafenib plus trametinib restored 131I uptake in patients with refractory BRAF p.V600E-mutated differentiated thyroid cancer; 38% of patients achieved a partial response 6 months after 131I administration.[87]
Use of this content is subject to our disclaimer